Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 6 » Issue 1

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole

Authors Marty Hinz, Alvin Stein, Thomas Uncini

Published 9 November 2010 Volume 2010:6(1) Pages 741—747

DOI https://doi.org/10.2147/NDT.S14353

Review by Single-blind

Peer reviewer comments 3

Marty Hinz1, Alvin Stein2, Thomas Uncini3
1Clinical Research, NeuroResearch Clinics, Inc., Cape Coral, FL, USA; 2Stein Orthopedic Associates, Plantation, FL, USA; 3DBS Labs, Duluth, MN, USA

Purpose: A novel method for differentiating and treating bipolar disorder cycling on the depressive pole from patients who are suffering a major depressive episode is explored in this work. To confirm the diagnosis of type 1 or type 2 bipolar disorder, the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria require that at least one manic or hypomanic episode be identified. History of one or more manic or hypomanic episodes may be impossible to obtain, representing a potential blind spot in the DSM-IV diagnostic criteria. Many bipolar patients who cycle primarily on the depressive side for many years carry a misdiagnosis of recurrent major depression, leading to treatment with antidepressants that achieve little or no relief of symptoms. This article discusses a novel approach for diagnosing and treating patients with bipolar disorder cycling on the depressive pole versus patients with recurrent major depression.
Patients and methods: Patients involved in this study were formally diagnosed with recurrent major depression under DSM-IV criteria and had no medical history of mania or hypomania to support the diagnosis of bipolar disorder. All patients had suffered multiple depression treatment failures in the past, when evaluated under DSM-IV guidelines, secondary to administration of antidepressant drugs and/or serotonin with dopamine amino acid precursors.
Results: This study contained 1600 patients who were diagnosed with recurrent major depression under the DSM-IV criteria. All patients had no medical history of mania or hypomania. All patients experienced no relief of depression symptoms on level 3 amino acid dosing values of the amino acid precursor dosing protocol. Of 1600 patients studied, 117 (7.3%) nonresponder patients were identified who experienced no relief of depression symptoms when the serotonin and dopamine amino acid precursor dosing values were adjusted to establish urinary serotonin and urinary dopamine levels in the Phase III therapeutic ranges. All of the 117 nonresponders who achieved no relief of depression symptoms were continued on this amino acid dosing value, and a mood-stabilizing drug was started. At this point, complete relief of depression symptoms, under evaluation with DSM-IV criteria, was noted in 114 patients within 1–5 days. With further dose adjustment of the mood-stabilizing drug, the remaining three nonresponders achieved relief of depression symptoms.
Conclusion: Resolution of depression symptoms with the addition of a mood-stabilizing drug in combination with proper levels of serotonin and dopamine amino acid precursors was the basis for a clinical diagnosis of bipolar disorder cycling on the depressive pole.

Keywords: depression, bipolar, serotonin, dopamine, mania, hypomania

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Parkinson's disease managing reversible neurodegeneration [Corrigendum]

Hinz M, Stein A, Cole T, McDougall B, Westaway M

Neuropsychiatric Disease and Treatment 2016, 12:1587-1588

Published Date: 28 June 2016

Amino acid management of Parkinson's disease: a case study [Corrigendum]

Hinz M, Stein A, Uncini T

International Journal of General Medicine 2016, 9:205-206

Published Date: 13 June 2016

Parkinson’s disease managing reversible neurodegeneration

Hinz M, Stein A, Cole T, McDougall B, Westaway M

Neuropsychiatric Disease and Treatment 2016, 12:763-775

Published Date: 5 April 2016

Relative nutritional deficiencies associated with centrally acting monoamines [Corrigendum]

Hinz M, Stein A, Uncini T

International Journal of General Medicine 2015, 8:163-164

Published Date: 22 April 2015

Parkinson’s disease-associated melanin steal

Hinz M, Stein A, Cole T

Neuropsychiatric Disease and Treatment 2014, 10:2331-2337

Published Date: 10 December 2014

Parkinson's disease: carbidopa, nausea, and dyskinesia

Hinz M, Stein A, Cole T

Clinical Pharmacology: Advances and Applications 2014, 6:189-194

Published Date: 14 November 2014

The Parkinson's disease death rate: carbidopa and vitamin B6

Hinz M, Stein A, Cole T

Clinical Pharmacology: Advances and Applications 2014, 6:161-169

Published Date: 21 October 2014

Administration of supplemental L-tyrosine with phenelzine: a clinical literature review

Hinz M, Stein A, Cole T, Ryan P

Clinical Pharmacology: Advances and Applications 2014, 6:107-110

Published Date: 22 July 2014

Management of L-dopa overdose in the competitive inhibition state

Hinz M, Stein A, Cole T

Drug, Healthcare and Patient Safety 2014, 6:93-99

Published Date: 22 July 2014

5-HTP efficacy and contraindications

Hinz M, Stein A, Uncini T

Neuropsychiatric Disease and Treatment 2012, 8:323-328

Published Date: 19 July 2012

Relative nutritional deficiencies associated with centrally acting monoamines

Hinz M, Stein A, Uncini T

International Journal of General Medicine 2012, 5:413-430

Published Date: 8 May 2012

The discrediting of the monoamine hypothesis

Hinz M, Stein A, Uncini T

International Journal of General Medicine 2012, 5:135-142

Published Date: 14 February 2012

Monoamine depletion by reuptake inhibitors

Hinz M, Stein A, Uncini T

Drug, Healthcare and Patient Safety 2011, 3:69-77

Published Date: 20 October 2011

APRESS: apical regulatory super system, serotonin, and dopamine interaction

Hinz M, Stein A, Uncini T

Neuropsychiatric Disease and Treatment 2011, 7:457-463

Published Date: 5 August 2011

Amino acid management of Parkinson’s disease: a case study

Marty Hinz, Alvin Stein, Thomas Uncini

International Journal of General Medicine 2011, 4:165-174

Published Date: 28 February 2011

Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine

Marty Hinz, Alvin Stein, Thomas Uncini

Research and Reports in Urology 2011, 3:19-24

Published Date: 4 February 2011

Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation

Marty Hinz, Alvin Stein, Robert Neff, et al

Neuropsychiatric Disease and Treatment 2011, 7:31-38

Published Date: 26 January 2011

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

Neurotransmitter testing of the urine: a comprehensive analysis

Marty Hinz, Alvin Stein, George Trachte, et al

Research and Reports in Urology 2010, 2:177-183

Published Date: 7 October 2010

The dual-gate lumen model of renal monoamine transport

Marty Hinz, Alvin Stein, Thomas Uncini

Neuropsychiatric Disease and Treatment 2010, 6:387-392

Published Date: 5 July 2010

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Particle size reduction to the nanometer range: a promising approach to improve buccal absorption of poorly water-soluble drugs

Rao S, Song Y, Peddie F, Evans AM

International Journal of Nanomedicine 2011, 6:1245-1251

Published Date: 20 June 2011

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010

The dual-gate lumen model of renal monoamine transport

Marty Hinz, Alvin Stein, Thomas Uncini

Neuropsychiatric Disease and Treatment 2010, 6:387-392

Published Date: 5 July 2010